Tivdak® (tisotumab vedotin-tftv)
Effective 11/01/2022

Plan	☒ MassHealth ☐Commercial/Exchange	**Program Type**	☒ Prior Authorization ☐ Quantity Limit ☐ Step Therapy
Benefit	☐ Pharmacy Benefit ☒ Medical Benefit (NLX)		
Specialty Limitations			
Contact Information	**Specialty Medications**		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview
Tivdak® (tisotumab vedotin-tftv) is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

No PA	Drugs that require PA
Alternatives vary by specific malignancy and may include systemic chemotherapy (e.g., platinum [cisplatin, carboplatin]-containing regimens).	Tivdak® (tisotumab vedotin-tftv)

Coverage Guidelines
Authorization may be reviewed on a case by case basis for members who are new to the plan currently receiving treatment with requested medication excluding when the product is obtained as samples or via manufacturer's patient assistance programs.
OR
Authorization may be granted for members when all the following criteria are met, and documentation is provided:

Recurrent or metastatic cervical cancer
Prescriber provides documentation of **ALL** of the following:
1. Appropriate diagnosis
2. Prescriber is an oncologist
3. Appropriate dosing (weight required)
4. Member is ≥18 years of age
5. Physician documentation of an inadequate response, adverse reaction, or contraindication to one line of platinum-based chemotherapy

6. If PD-L1 positive, physician documentation of member having an inadequate response, adverse reaction, or contraindication to **ONE** of the following:
    a. Keytruda® (pembrolizumab)
    b. Opdivo® (nivolumab)

Continuation of Therapy

Reauthorizations requires physician attestation of continuation of therapy and positive response to therapy.

Limitations

1. Initial approvals will be granted for 6 months.
2. Reauthorizations will be granted for 12 months.

References

1. Tivdak® (tisotumab vedotin-tftv) [prescribing information]. Bothell (WA): Seagen, Inc; 2021 Sep.
2. Duska LR**.** Overview of approach to cervical cancer survivors**.** In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2021 [cited 2021 Nov 19]. Available from: http://www.utdol.com/utd/index.do.
3. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program, Cancer stat facts: cervical cancer. 2021 [cited 2021 Nov 29]. Available from: Cervical Cancer — Cancer Stat Facts.
4. Wright J**.** Management of recurrent or metastatic cervical cancer**.** In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2021 [cited 2021 Nov 19]. Available from: http://www.utdol.com/utd/index.do
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Cervical Cancer. Version 1.2022. 2021 Oct 26 [cited 2021 Nov 19]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf.

Review History

09/21/22 – Created for September P&T. Matched MH criteria. Effective 11/1/22.

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.